- People Heart & Healthcare Center
- peoplehearthealth@gmail.com
- (91) 9772365365
Body Detox Treatment (BDT)
Body Detox Treatment (BDT), commonly known as chelation or kelation treatment or Detox Treatment, is a specialized therapy designed for effective Body Detox and cleansing. In this treatment, a combination of allopathic medicines is given via IV Line. The combination comprises EDTA (main chelating agent), Hyperine, Mgs, and SBS along with multivitamins and nutrients in a specific formulation.
- The main application of BDT is the body detox process that removes toxic substances from the system. EDTA is a US FDA–approved medicine for metal and lead toxicity.
- In our long experience, many patients with hard calcified blockages in heart arteries have shown significant improvement through BDT. Hard plaques become soft and, in some cases, blockages are reduced as well.
- In our BDT treatment, we administer heart-healthy vitamins and nutrients that naturally support and boost heart health while contributing to a complete body detox.
- A full cycle of BDT includes 20–25 sessions performed at 2–4 day intervals, with regular measurement of creatinine and urea levels. Each session lasts about 1.5–2.5 hours.
- We provide BDT strictly for detoxification purposes with complete patient consent.
In USA a medical research study named TACT TRIAL is also done, the detail of the trial is
TACT TRIAL – A Study That Proved Effectiveness of Chelation Treatment
In the USA, a medical research study called the TACT Trial was conducted to evaluate EDTA chelation therapy. This study proved the significant benefits of chelation in cardiovascular disease—highlighting not only heart health improvement but also deeper Body Detox effects.
The TACT (Trial to Assess Chelation Therapy) Study by NIH showed remarkable results:
- Up to 50% prevention of recurrent heart attacks
- 43% reduction in death rate from all causes
- Among diabetic patients (one-third of 1,708 participants):
- 41% reduction in overall cardiovascular risk
- 40% reduction in death from heart disease
- Reduced risk of nonfatal stroke or nonfatal heart attack
- 52% reduction in recurrent heart attacks
- 43% reduction in death from any cause
This randomized, placebo-controlled study demonstrated that intravenous disodium EDTA chelation therapy significantly decreased subsequent cardiac events when compared to patients receiving placebo.
Cardiologists from major medical institutions and 134 medical centers across the U.S. and Canada conducted this $30 million study. Statistical analysis showed highly significant benefits: fewer deaths, fewer heart attacks, fewer strokes, less need for cardiovascular surgery, and fewer hospitalizations for heart-related issues. Chelation therapy was shown to be safe, with no serious side effects. Patients continued to experience increasing benefits for up to five years.
A total of 40 three-hour intravenous infusions of disodium EDTA were administered over 30 weekly sessions, followed by 10 monthly treatments.
All participants had previously suffered a well-documented heart attack. Results showed reduced overall death rates and fewer cardiovascular events. Diabetic patients responded especially well. The investigators concluded that intravenous EDTA chelation therapy could safely offer significant benefits to heart disease patients already on standard therapies—while also enhancing the body detox process.
These findings were unexpected by many cardiologists, prompting additional research to confirm and understand the mechanism behind these results.